Gene · 7292
Papers4,164
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
221 to 240 of 4,164
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Alopecia areata exhibits cutaneous and systemic OX40 activation across atopic backgrounds. | Allergy | 2024 | 39115359 | PubTator, text mining | PubMed |
| Immune checkpoint reprogramming via sequential nucleic acid delivery strategy optimizes systemic immune responses for gastrointestinal cancer immunotherapy. | Cancer Lett | 2024 | 39094825 | PubTator, text mining | PubMed |
| The Immunological Profile of Adipose Mesenchymal Stromal/Stem Cells after Cell Expansion and Inflammatory Priming. | Biomolecules | 2024 | 39062566 | PubTator, text mining | PubMed |
| Fungal Head and Neck Dermatitis: Current Understanding and Management. | Clin Rev Allergy Immunol | 2024 | 39031274 | PubTator, text mining | PubMed |
| Cross-talk between ILC2 and Gata3high Tregs locally constrains adaptive type 2 immunity. | Sci Immunol | 2024 | 39028828 | PubTator, text mining | PubMed |
| Association between OX40L polymorphism and type 2 diabetes mellitus in Iranians. | BMC Med Genomics | 2024 | 38982447 | PubTator, text mining | PubMed |
| Immune checkpoint expression as prognostic biomarker candidates in non-small cell lung carcinoma patients. | J Surg Oncol | 2024 | 38973141 | PubTator, text mining | PubMed |
| CTHRC1 is a prognostic biomarker correlated with immune infiltration in head and neck squamous cell carcinoma. | BMC Oral Health | 2024 | 38937712 | PubTator, text mining | PubMed |
| The role of OX40 ligand/OX40 axis signalling in atopic dermatitis. | Br J Dermatol | 2024 | 38836560 | PubTator, text mining | PubMed |
| Prognostic value of genomic mutation signature associated with immune microenvironment in southern Chinese patients with esophageal squamous cell carcinoma. | Cancer Immunol Immunother | 2024 | 38832974 | PubTator, text mining | PubMed |
| The Future of Atopic Dermatitis Treatment. | Adv Exp Med Biol | 2024 | 38724797 | PubTator, text mining | PubMed |
| Expression patterns of novel immunotherapy targets in intermediate- and high-grade lung neuroendocrine neoplasms. | Cancer Immunol Immunother | 2024 | 38693435 | PubTator, text mining | PubMed |
| Biologic and small-molecule therapy for treating moderate to severe atopic dermatitis: Mechanistic considerations. | J Allergy Clin Immunol | 2024 | 38670231 | PubTator, text mining | PubMed |
| Regulation of the Function of T Follicular Helper Cells and B Cells in Type 1 Diabetes Mellitus by the OX40/OX40L Axis. | J Clin Endocrinol Metab | 2024 | 38625053 | PubTator, text mining | PubMed |
| An OX-Tra'Ordinary Tale: The Role of OX40 and OX40L in Atopic Dermatitis. | Cells | 2024 | 38607026 | PubTator, text mining | PubMed |
| Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma. | Genome Med | 2024 | 38566201 | PubTator, text mining | PubMed |
| OX40/OX40 ligand and its role in precision immune oncology. | Cancer Metastasis Rev | 2024 | 38526805 | PubTator, text mining | PubMed |
| Association of OX40L gene polymorphism with multiple sclerosis in Iranians. | Heliyon | 2024 | 38496859 | PubTator, text mining | PubMed |
| Retrospective Analyses of PD-L1, LAG-3, TIM-3, OX40L Expressions and MSI Status in Gastroenteropancreatic Neuroendocrine Neoplasms. | Cancer Invest | 2024 | 38486421 | PubTator, text mining | PubMed |
| Cross-talk between disulfidptosis and immune check point genes defines the tumor microenvironment for the prediction of prognosis and immunotherapies in glioblastoma. | Sci Rep | 2024 | 38365809 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7292/papers?page=12